PTC Therapeutics Wins $211M Bankruptcy Auction for Sangamo’s Fabry Disease Gene Therapy

Company: PTC Therapeutics · Event Type: Bankruptcy Asset Acquisition · Product: ST-920 (isaralgagene civaparvovec) · Mechanism: AAV-Delivered GLA Gene Replacement · Indication: Fabry Disease · Deal Value: $111M Upfront, Up To $100M In Milestones · Announcement Date: August 13, 2026 Summary PTC Therapeutics has agreed…